Switch theme
Sign up to access all valuation multiples
LigaChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation.
2006
n/a
LTM Revenue $110M
LTM EBITDA -$2.4M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LigaChem Biosciences has a last 12-month revenue (LTM) of $110M and a last 12-month EBITDA of -$2.4M.
In the most recent fiscal year, LigaChem Biosciences achieved revenue of $91.5M and an EBITDA of $10.6M.
LigaChem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LigaChem Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $91.5M | XXX | XXX | XXX |
| Gross Profit | $98.7M | XXX | $79.9M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | -$2.4M | XXX | $10.6M | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | 12% | XXX | XXX | XXX |
| EBIT | -$4.7M | XXX | -$15.2M | XXX | XXX | XXX |
| EBIT Margin | -4% | XXX | -17% | XXX | XXX | XXX |
| Net Profit | $17.2M | XXX | $5.7M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LigaChem Biosciences's stock price is KRW 114900 (or $84).
LigaChem Biosciences has current market cap of KRW 4.17T (or $3.0B), and EV of KRW 3.70T (or $2.7B).
See LigaChem Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $3.0B | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LigaChem Biosciences has market cap of $3.0B and EV of $2.7B.
LigaChem Biosciences's trades at 29.4x EV/Revenue multiple, and 253.0x EV/EBITDA.
Equity research analysts estimate LigaChem Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LigaChem Biosciences has a P/E ratio of 175.9x.
See valuation multiples for LigaChem Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 24.4x | XXX | 29.4x | XXX | XXX | XXX |
| EV/EBITDA | -1116.9x | XXX | 253.0x | XXX | XXX | XXX |
| EV/EBIT | -571.6x | XXX | -177.1x | XXX | XXX | XXX |
| EV/Gross Profit | 27.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 175.9x | XXX | 534.5x | XXX | XXX | XXX |
| EV/FCF | 75.7x | XXX | 50.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLigaChem Biosciences's last 12 month revenue growth is 52%
LigaChem Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
LigaChem Biosciences's rule of 40 is -155% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LigaChem Biosciences's rule of X is 127% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LigaChem Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 52% | XXX | 52% | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | -1661% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -155% | XXX | 63% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 127% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 104% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LigaChem Biosciences acquired XXX companies to date.
Last acquisition by LigaChem Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . LigaChem Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LigaChem Biosciences founded? | LigaChem Biosciences was founded in 2006. |
| Where is LigaChem Biosciences headquartered? | LigaChem Biosciences is headquartered in South Korea. |
| Who is the CEO of LigaChem Biosciences? | LigaChem Biosciences's CEO is Mr. Yong-Ju Kim. |
| Is LigaChem Biosciences publicy listed? | Yes, LigaChem Biosciences is a public company listed on KRX. |
| What is the stock symbol of LigaChem Biosciences? | LigaChem Biosciences trades under 141080 ticker. |
| When did LigaChem Biosciences go public? | LigaChem Biosciences went public in 2013. |
| Who are competitors of LigaChem Biosciences? | Similar companies to LigaChem Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LigaChem Biosciences? | LigaChem Biosciences's current market cap is $3.0B |
| What is the current revenue of LigaChem Biosciences? | LigaChem Biosciences's last 12 months revenue is $110M. |
| What is the current revenue growth of LigaChem Biosciences? | LigaChem Biosciences revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of LigaChem Biosciences? | Current revenue multiple of LigaChem Biosciences is 24.4x. |
| Is LigaChem Biosciences profitable? | Yes, LigaChem Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LigaChem Biosciences? | LigaChem Biosciences's last 12 months EBITDA is -$2.4M. |
| What is LigaChem Biosciences's EBITDA margin? | LigaChem Biosciences's last 12 months EBITDA margin is -2%. |
| What is the current EV/EBITDA multiple of LigaChem Biosciences? | Current EBITDA multiple of LigaChem Biosciences is -1116.9x. |
| What is the current FCF of LigaChem Biosciences? | LigaChem Biosciences's last 12 months FCF is $35.6M. |
| What is LigaChem Biosciences's FCF margin? | LigaChem Biosciences's last 12 months FCF margin is 32%. |
| What is the current EV/FCF multiple of LigaChem Biosciences? | Current FCF multiple of LigaChem Biosciences is 75.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
